Back

STING agonist-mediated endothelial cell activation drives NK cells and neutrophils-dependent pulmonary inflammation

Chen, C.; Zhao, Y.; Du, F.; Liu, R.; Zheng, X.; Wu, S.; Wang, Y.; Qiu, F.; Chen, L.; Chen, R.; Li, F.; Gong, L.; Long, Y.

2026-03-12 pharmacology and toxicology
10.64898/2026.03.10.710764 bioRxiv
Show abstract

Stimulator of interferon genes (STING) agonists and derivative molecules have been extensively developed for tumor immunotherapy. However, systemic exposure toxicity risks have constrained clinical trial progression and even threatened patient lives. Currently, systematic toxicity assessments for STING agonists remain lacking, with the mode of action for major organ injury yet to be elucidated. Here, we focused on STING agonist-induced lung injury, revealing that systemic administration of STING agonists caused pulmonary hemorrhage, inflammatory alterations, and respiratory dysfunction. Through single-cell RNA sequencing and immune deletion studies, we found that lung endothelial cells could be stimulated by STING agonists and then secreted chemokines and IL-15 to recruit and activate NK cells. NK cells could induce endothelial cell apoptosis via IFN-{gamma}. Tbx21+ NK subpopulations, which activated by endothelial cells, could produce chemokines to recruit neutrophils. Neutrophils secreted IL-1{beta} through positive feedback pathways and form neutrophil extracellular traps during lung injury. This study elucidates the critical role of the endothelial cell-NK cell-neutrophil axis in mediating STING agonist-associated pneumonia, offering insights for developing intervention strategies for STING agonist toxicity.

Matching journals

The top 13 journals account for 50% of the predicted probability mass.

1
Nature Communications
4913 papers in training set
Top 17%
10.3%
2
Advanced Science
249 papers in training set
Top 2%
7.3%
3
Clinical and Translational Medicine
30 papers in training set
Top 0.1%
6.5%
4
ACS Nano
99 papers in training set
Top 0.7%
4.9%
5
Signal Transduction and Targeted Therapy
29 papers in training set
Top 0.2%
4.0%
6
Cancer Letters
32 papers in training set
Top 0.1%
3.6%
7
Science Advances
1098 papers in training set
Top 8%
3.1%
8
Science Translational Medicine
111 papers in training set
Top 2%
2.4%
9
Scientific Reports
3102 papers in training set
Top 49%
2.1%
10
eLife
5422 papers in training set
Top 35%
2.1%
11
Cell Metabolism
49 papers in training set
Top 1%
1.7%
12
Biomaterials
78 papers in training set
Top 0.5%
1.7%
13
Experimental & Molecular Medicine
14 papers in training set
Top 0.1%
1.7%
50% of probability mass above
14
Journal of Controlled Release
39 papers in training set
Top 0.6%
1.5%
15
Nature Biotechnology
147 papers in training set
Top 5%
1.5%
16
PLOS ONE
4510 papers in training set
Top 58%
1.4%
17
Communications Biology
886 papers in training set
Top 14%
1.2%
18
Molecular Therapy
71 papers in training set
Top 2%
1.2%
19
JCI Insight
241 papers in training set
Top 5%
1.0%
20
ACS Pharmacology & Translational Science
40 papers in training set
Top 0.7%
1.0%
21
Cell Discovery
54 papers in training set
Top 4%
0.9%
22
The Journal of Infectious Diseases
182 papers in training set
Top 4%
0.9%
23
mBio
750 papers in training set
Top 10%
0.9%
24
Cell Reports Medicine
140 papers in training set
Top 7%
0.8%
25
Advanced Healthcare Materials
71 papers in training set
Top 1%
0.8%
26
iScience
1063 papers in training set
Top 29%
0.8%
27
Angewandte Chemie International Edition
81 papers in training set
Top 3%
0.8%
28
Protein & Cell
25 papers in training set
Top 2%
0.8%
29
Cell Death Discovery
51 papers in training set
Top 1%
0.8%
30
Cell Stem Cell
57 papers in training set
Top 2%
0.8%